BRPI1012523A2 - composições biodisponíveis de composto de alfa-(n-sulfonamido) acetamida amorfo - Google Patents

composições biodisponíveis de composto de alfa-(n-sulfonamido) acetamida amorfo

Info

Publication number
BRPI1012523A2
BRPI1012523A2 BRPI1012523A BRPI1012523A BRPI1012523A2 BR PI1012523 A2 BRPI1012523 A2 BR PI1012523A2 BR PI1012523 A BRPI1012523 A BR PI1012523A BR PI1012523 A BRPI1012523 A BR PI1012523A BR PI1012523 A2 BRPI1012523 A2 BR PI1012523A2
Authority
BR
Brazil
Prior art keywords
sulfonamido
acetamide compound
amorphous alpha
bioavailable compositions
bioavailable
Prior art date
Application number
BRPI1012523A
Other languages
English (en)
Inventor
Feng Qian
Raja M Haddadin
Ruiling F Hartley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI1012523A2 publication Critical patent/BRPI1012523A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI1012523A 2009-04-14 2010-04-12 composições biodisponíveis de composto de alfa-(n-sulfonamido) acetamida amorfo BRPI1012523A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16906609P 2009-04-14 2009-04-14
PCT/US2010/030679 WO2010120662A2 (en) 2009-04-14 2010-04-12 Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
BRPI1012523A2 true BRPI1012523A2 (pt) 2016-03-29

Family

ID=42664672

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012523A BRPI1012523A2 (pt) 2009-04-14 2010-04-12 composições biodisponíveis de composto de alfa-(n-sulfonamido) acetamida amorfo

Country Status (21)

Country Link
US (1) US20100261768A1 (pt)
EP (1) EP2419086B1 (pt)
JP (1) JP2012524090A (pt)
KR (1) KR20120027142A (pt)
CN (1) CN102387788B (pt)
AR (1) AR076306A1 (pt)
AU (1) AU2010236701A1 (pt)
BR (1) BRPI1012523A2 (pt)
CA (1) CA2758709A1 (pt)
DK (1) DK2419086T3 (pt)
EA (1) EA201171207A1 (pt)
ES (1) ES2426403T3 (pt)
HR (1) HRP20130807T1 (pt)
MX (1) MX2011010513A (pt)
NZ (1) NZ595411A (pt)
PL (1) PL2419086T3 (pt)
PT (1) PT2419086E (pt)
SI (1) SI2419086T1 (pt)
SM (1) SMT201300106B (pt)
TW (1) TW201043269A (pt)
WO (1) WO2010120662A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053912A1 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201311240A (zh) * 2011-07-21 2013-03-16 必治妥美雅史谷比公司 非晶形哌啶基化合物之生物可利用組合物
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
TWI718102B (zh) * 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3999007A (en) * 1975-10-09 1976-12-21 Carl Joseph Crane Aircraft visual approach/landing reproducer device and system
US5136301A (en) * 1989-08-30 1992-08-04 Rockwell International Corporation Primary flight display system having a vertical linear altimeter
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
DE69606804T2 (de) * 1995-06-20 2000-06-15 Honeywell Inc Integriertes System zur Grundkollisionsvermeidung
US5977141A (en) * 1995-11-17 1999-11-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
US6233522B1 (en) * 1998-07-06 2001-05-15 Alliedsignal Inc. Aircraft position validation using radar and digital terrain elevation database
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6570531B1 (en) * 2000-04-27 2003-05-27 Rockwell Collins, Inc. Satellite navigation receiver designed for compatibility with aircraft automatic landing systems
US6483454B1 (en) * 2000-11-28 2002-11-19 Bae Systems Aerospace Inc. Close formation aircraft collision avoidance
WO2003053912A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS
JP2006522126A (ja) * 2003-03-31 2006-09-28 ワイス βアミロイド生産のフルオロ含有およびトリフルオロアルキル含有複素環スルホンアミド阻害物質およびその誘導体
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
FR2870605B1 (fr) * 2004-05-18 2010-10-08 Airbus France Procede et dispositif de guidage automatique d'un aeronef, pour un vol au moins en partie a basse altitude
FR2880456B1 (fr) * 2005-01-03 2007-02-23 Airbus France Sas Procede et dispositif d'alerte sonore lors de la desactivation d'un pilote automatique d'un aeronef
FR2886439B1 (fr) * 2005-05-24 2010-11-05 Eurocopter France Procede et dispositif d'aide au pilotage d'un aeronef a basse altitude
JP5284101B2 (ja) * 2005-11-09 2013-09-11 ノバルティス アーゲー 一時可塑剤を用いる医薬組成物の製造法
FR2897448B1 (fr) * 2006-02-14 2008-03-14 Airbus France Sas Procede et systeme d'aide au pilotage d'un aeronef.
AU2007217965A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
CN101384579A (zh) * 2006-02-17 2009-03-11 惠氏公司 2-氨基三氟烷基取代的醇的选择性n-磺酰化
MX2008011976A (es) * 2006-03-20 2009-04-07 Vertex Pharma Composiciones farmaceuticas.
CN101494979A (zh) * 2006-03-20 2009-07-29 沃泰克斯药物股份有限公司 药物组合物
FR2911988B1 (fr) * 2007-01-26 2016-03-25 Airbus France Procede et dispositif pour determiner une hauteur maximale de stabilisation lors de la phase finale de vol d'un avion
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Also Published As

Publication number Publication date
EA201171207A1 (ru) 2012-03-30
CN102387788A (zh) 2012-03-21
WO2010120662A2 (en) 2010-10-21
NZ595411A (en) 2013-02-22
US20100261768A1 (en) 2010-10-14
EP2419086B1 (en) 2013-06-26
KR20120027142A (ko) 2012-03-21
AU2010236701A1 (en) 2011-10-20
MX2011010513A (es) 2011-11-29
PL2419086T3 (pl) 2013-11-29
WO2010120662A3 (en) 2011-09-15
SMT201300106B (it) 2013-11-08
CA2758709A1 (en) 2010-10-21
CN102387788B (zh) 2013-07-10
AR076306A1 (es) 2011-06-01
DK2419086T3 (da) 2013-09-30
EP2419086A2 (en) 2012-02-22
HRP20130807T1 (hr) 2013-09-30
JP2012524090A (ja) 2012-10-11
ES2426403T3 (es) 2013-10-23
TW201043269A (en) 2010-12-16
SI2419086T1 (sl) 2013-10-30
PT2419086E (pt) 2013-09-04

Similar Documents

Publication Publication Date Title
HRP20130807T1 (hr) Bioraspoloživi sastavi tvari amorfnog alfa-(n-sulfonamido)acetamida
HK1155161A1 (en) Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound
TWI365185B (en) Amidophenoxyindazoles useful as inhibitors of c-met
EP2280916A4 (en) HYDROCHLORFLUOROLEFINZUSAMMENSETZUNGEN
BR112012005237A2 (pt) utilização de composições ternárias
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
BRPI1014706A2 (pt) indicação de capacidade de acesso de protocolo de internet local
DK2262793T3 (da) Krystallinske former af nilotinib-hci
BR112012007952A2 (pt) composição detergente
BR112012005039A2 (pt) Composição detergente
HK1164698A1 (en) Crystalline forms of genistein
IL264118A (en) Pharmaceutical preparation of amorphous acyl sulfonamide
BRPI0911678A2 (pt) forma cristalina anidrosa de maleato de orvepitant
BRPI1007452A2 (pt) formulações galênicas de compostos orgânicos
BR112012005611A2 (pt) composições detergente
ZA201106206B (en) A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
ZA201109045B (en) Crystalline form of pemirolast
EP2512247A4 (en) NOVEL THIOPHEN INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE
CU23884B1 (es) Derivados de dibenzotiazepina
ZA201004762B (en) Crystalline form of abacavir that is essentially free of solvent
DK2405911T3 (da) Anvendelse af atorvastatin lactoler som medikamenter
BRPI1009468A2 (pt) formulações galênicas de compostos orgânicos
PL2408799T3 (pl) Nowa krystaliczna postać anty-progesteronu CDB-4124
HUP0800755A2 (en) Crystalline forms of rosiglitazone
TH105747B (th) รูปแบบผลึกของไนโตรเคทิคอล

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]